Antimicrobial
Lipoglycopeptides
Lipid-tailed glycopeptides for Gram-positives
LY-poh-gly-koh-PEP-tydz
High-yield clue
A vancomycin-like core binds D-Ala-D-Ala; the lipid tail anchors the drug in the membrane, and telavancin and oritavancin add membrane depolarization while dalbavancin acts essentially like vancomycin.
Overview
An antibacterial class (telavancin, dalbavancin, oritavancin) of glycopeptides carrying a lipophilic tail, used to teach cell-wall inhibition anchored by a membrane-binding tail in Gram-positives.
Classification
- Antibacterial
- Glycopeptide derivative
- Lipophilic side chain
- Gram-positive spectrum
Lab & identification clues
- Binds terminal D-alanyl-D-alanine to block peptidoglycan cross-linking vocabulary
- Membrane depolarization / permeability concept for telavancin and oritavancin
- Long half-life vocabulary (dalbavancin, oritavancin)
Associations
- Resistant Gram-positive study association (MRSA)
- Cell-wall synthesis inhibition concept
- Related to vancomycin lineage vocabulary
Commonly confused with
- Vancomycin (glycopeptide)
- Lipopeptides (daptomycin)
Frequently asked questions
What is Lipoglycopeptides?
An antibacterial class (telavancin, dalbavancin, oritavancin) of glycopeptides carrying a lipophilic tail, used to teach cell-wall inhibition anchored by a membrane-binding tail in Gram-positives.
What is the high-yield clue for Lipoglycopeptides?
A vancomycin-like core binds D-Ala-D-Ala; the lipid tail anchors the drug in the membrane, and telavancin and oritavancin add membrane depolarization while dalbavancin acts essentially like vancomycin.
What is Lipoglycopeptides associated with?
Lipoglycopeptides is associated with Resistant Gram-positive study association (MRSA), Cell-wall synthesis inhibition concept, and Related to vancomycin lineage vocabulary.
What is Lipoglycopeptides commonly confused with?
Lipoglycopeptides is commonly confused with Vancomycin (glycopeptide) and Lipopeptides (daptomycin).
Original mechanism summary for microbiology study. Sources checked: CDC antimicrobial-resistance guidance, NCBI Bookshelf Medical Microbiology, and standard coursework frameworks; reviewed 2026-06. Covers class, mechanism, and resistance vocabulary only; no prescribing, dosing, or patient-specific treatment guidance.